Clinical trials: sponsored by Shionogi
Dyslipidemia
Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels
The purpose of this study is to evaluate safety of JTT-705 and to demonstrate efficacy of JTT-705 compared with placebo when co-administered with atorvastatin 20 mg in patients with low HDL
- Trial name
- NCT00689442
- Testing
- JTT-705 600 mg and atorvastatin 20 mg
- Where
- Netherlands
- Volunteers
- 105 people
- Sponsor
- Shionogi Inc.
Dyslipidemia
Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels
The purpose of this study is to evaluate safety of JTT-705 and to demonstrate efficacy of JTT-705 compared with placebo when co-administered with simvastatin 40 mg in patients with low HDL
- Trial name
- NCT00688558
- Testing
- JTT-705 600 mg and simvastatin 40 mg
- Where
- Netherlands
- Volunteers
- 92 people
- Sponsor
- Shionogi Inc.
Type II Hyperlipidemia
Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia
The purpose of this study is to evaluate the effect of two dose levels of JTT-705 when co-administered with pravastatin 40 mg on HDL-C and LDL-C and the inhibition rate of CETP activity and to document short term safety.
- Trial name
- NCT00688896
- Testing
- JTT-705 600 mg and pravastatin 40 mg, JTT-705 300 mg and pravastatin 40 mg
- Where
- Netherlands
- Volunteers
- 155 people
- Sponsor
- Shionogi Inc.
Premenopause
Clinical Pharmacological Study of GnRH Antagonist, Cetrorelix for Healthy Female Volunteer
GnRH analogs are globally used for assisted reproduction in infertile patients. To date, in healthy female volunteers the pharmacokinetic and pharmacodynamic profiles of cetrorelix when administered in a single dose have been…
- Trial name
- NCT00628121
- Testing
- Cetrorelix
- Where
- Japan
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Nippon Kayaku Co., Ltd.